Autopsy report · NCT02065869
Safety Study of Gene Modified Donor T-cells Following TCRαβ+ Depleted Stem Cell Transplant
Cause of deathFunding or business
“Sponsor decision”
Life of this trial
- Registered 2 months before it started.
- Ran for about 7 years 5 months before it stopped.
- 187 participants enrolled.
- Results were posted on the registry 1 year 4 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1, Phase 2
- Sponsor
- Bellicum Pharmaceuticals
- Sponsor type
- Industry
- Conditions
- Acute Lymphoblastic Leukemia; Leukemia, Acute Myeloid (AML), Child; Lymphoma, Non-Hodgkin; Myelodysplastic Syndrome; Primary Immunodeficiency; Anemia, Aplastic
- Interventions
- BPX-501 T cells; Rimiducid
- Participants
- 187
- Sites
- 4
- Countries
- Italy, United Kingdom
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.